Drug Profile
Research programme: typhoid vaccine - National Resilience
Alternative Names: GelVac® typhoid vaccineLatest Information Update: 14 Nov 2021
Price :
$50
*
At a glance
- Originator DelSite Biotechnologies
- Developer DelSite Biotechnologies; National Resilience
- Class Bacterial vaccines; Drug conjugates
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Typhoid
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Typhoid in USA (Parenteral, Injection)
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 25 May 2007 Preclinical trials in Typhoid in USA (Parenteral)